FDA to review ranitidine after detecting cancer-causing contamination
The US Food and Drug Administration (FDA) has issued a statement regarding the safety of the drug ranitidine after the detection of N-nitrosodimethylamine (NDMA) in some samples.
Takeda submits NDA for SC formation of ulcerative colitis treatment
Takeda Pharmaceutical has submitted a new drug application (NDA) in Japan for a subcutaneous (SC) formulation of vedolizumab to treat adults with moderately to severely active ulcerative colitis (UC).
Takeda takes a step forward in becoming dominant player in IBD landscape
The Japanese drugmaker intends to make Entyvio available in both a pre-filled syringe as well as a pen to add to its currently approved intravenous formulation.
Will value-based pricing be a trump card for Takeda’s Alofisel?
GlobalData expects new pricing scheme will provide Takeda greater clout to negotiate with the cost-conscious authorities of the EU.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.